We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
-4%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.26B
AUM Growth
-$362M
Cap. Flow
-$5M
Cap. Flow %
-0.12%
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17

Top Buys

Rank Stock Value
1
PM icon
Philip Morris
PM
+$38.3M
2
AMZN icon
Amazon
AMZN
+$27.7M
3
PLTR icon
Palantir
PLTR
+$17.5M
4
HIMS icon
Hims & Hers Health
HIMS
+$13.7M
5
YUMC icon
Yum China
YUMC
+$13.2M

Top Sells

Rank Stock Value
1
PDD icon
Pinduoduo
PDD
+$39.4M
2
NVDA icon
NVIDIA
NVDA
+$30.1M
3
META icon
Meta Platforms (Facebook)
META
+$14.9M
4
BEKE icon
KE Holdings
BEKE
+$14.1M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$11.2M

Sector Composition

Rank Sector Weight
1 Technology 42.45%
2 Consumer Discretionary 16.26%
3 Communication Services 14.17%
4 Healthcare 8.06%
5 Consumer Staples 5.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
551
Theravance Biopharma
TBPH
$873M
$11.2K ﹤0.01%
1,258
+225
+22% +$2.09K
RLAY icon
552
Relay Therapeutics
RLAY
$4.24B
$11.2K ﹤0.01%
4,286
+771
+22% +$3.02K
PAHC icon
553
Phibro Animal Health
PAHC
$1.48B
$11.1K ﹤0.01%
520
+93
+22% +$2.08K
INN
554
Summit Hotel Properties
INN
$748M
$11K ﹤0.01%
2,033
+80
+4% +$508
DFTX
555
Definium Therapeutics
DFTX
$5.91B
$11K ﹤0.01%
1,877
+337
+22% +$2.41K
PHAT icon
556
Phathom Pharmaceuticals
PHAT
$720M
$11K ﹤0.01%
1,751
+315
+22% +$1.91K
PGEN icon
557
Precigen
PGEN
$2.12B
$10.8K ﹤0.01%
+7,259
New +$11.4K
KROS icon
558
Keros Therapeutics
KROS
$202M
$10.6K ﹤0.01%
1,036
+192
+23% +$2.23K
XRN
559
Chiron Real Estate Inc
XRN
$516M
$10.5K ﹤0.01%
240
+15
+7% +$620
ZVRA icon
560
Zevra Therapeutics
ZVRA
$570M
$10.2K ﹤0.01%
1,367
+246
+22% +$1.96K
MESO
561
Mesoblast
MESO
$1.89B
$10.2K ﹤0.01%
817
+146
+22% +$2.4K
UHT
562
Universal Health Realty Income Trust
UHT
$608M
$10.1K ﹤0.01%
247
+10
+4% +$393
ORIC icon
563
Oric Pharmaceuticals
ORIC
$1.2B
$10.1K ﹤0.01%
1,807
+325
+22% +$2.84K
SIGA icon
564
SIGA Technologies
SIGA
$233M
$10K ﹤0.01%
1,828
+329
+22% +$1.95K
TRML
565
DELISTED
Tourmaline Bio
TRML
$9.98K ﹤0.01%
656
+118
+22% +$1.89K
ERAS icon
566
Erasca
ERAS
$6.48B
$9.92K ﹤0.01%
7,240
+1,304
+22% +$2.24K
VERV
567
DELISTED
Verve Therapeutics
VERV
$9.9K ﹤0.01%
2,167
+389
+22% +$2.61K
SANA icon
568
Sana Biotechnology
SANA
$904M
$9.6K ﹤0.01%
5,716
+1,028
+22% +$2.87K
CRMD icon
569
CorMedix
CRMD
$588M
$9.57K ﹤0.01%
1,554
+280
+22% +$2.9K
CHCT
570
Community Healthcare Trust
CHCT
$530M
$9.57K ﹤0.01%
527
+21
+4% +$401
FPI
571
Farmland Partners
FPI
$411M
$9.57K ﹤0.01%
858
+33
+4% +$380
BCYC
572
Bicycle Therapeutics
BCYC
$280M
$9.56K ﹤0.01%
1,126
+202
+22% +$2.38K
EYPT icon
573
EyePoint Inc
EYPT
$1.08B
$9.47K ﹤0.01%
1,747
+314
+22% +$2.2K
RAPP
574
Rapport Therapeutics
RAPP
$2.05B
$9.39K ﹤0.01%
936
+168
+22% +$2.18K
ALX
575
Alexander's
ALX
$1.36B
$9.2K ﹤0.01%
44
+3
+7% +$607
21 22
23
24 25

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GF Fund Management's Q1 2025 Portfolio in Review

As of Q1 2025, GF Fund Management held 683 positions worth $4.26B, down 7.8% from $4.62B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

GF Fund Management's Q1 2025 filing shows 46 new, 475 increased, 93 reduced and 17 closed positions. Its largest new stake was Hims & Hers Health: 368,661 shares worth $10.9M. The largest sale was Pinduoduo, an estimated $39.4M.

By sector, the portfolio is most concentrated in Technology at 42% of assets, down from 45% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • GF Fund Management's largest Q1 2025 buy was Hims & Hers Health: 368,661 shares worth $10.9M.
  • GF Fund Management added most to Philip Morris in Q1 2025, an estimated $38.3M increase.
  • GF Fund Management's biggest Q1 2025 reduction was Pinduoduo, cutting an estimated $39.4M.
  • GF Fund Management fully exited Applied Optoelectronics in Q1 2025, selling an estimated $5.07M.
  • GF Fund Management's ten largest holdings make up 44% of its $4.26B portfolio in Q1 2025.
  • GF Fund Management opened 46 new positions and closed 17 in Q1 2025.
  • GF Fund Management's portfolio value fell 7.8% quarter-over-quarter to $4.26B.

Based on GF Fund Management's 13F filing for Q1 2025, filed 29 Apr 2025.